Free tool
FAERS Monitor: Aldurazyme
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125058 or its brand name (Aldurazyme, Laronidase). Reports on generic versions are filed under their own applications.
Reports
4,133
Serious
2,841
69% of reports
Hospitalization
1,423
Death reported
671
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia517
- pneumonia246
- vomiting207
- dyspnoea198
- malaise190
- cough187
- fatigue151
- death141
- headache133
- influenza131
- pain128
- condition aggravated127
- inappropriate schedule of product administration119
- urticaria118
- nasopharyngitis107
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 81 |
| 2005 | 60 |
| 2006 | 28 |
| 2007 | 111 |
| 2008 | 61 |
| 2009 | 59 |
| 2010 | 51 |
| 2011 | 73 |
| 2012 | 90 |
| 2013 | 132 |
| 2014 | 133 |
| 2015 | 208 |
| 2016 | 249 |
| 2017 | 264 |
| 2018 | 325 |
| 2019 | 261 |
| 2020 | 259 |
| 2021 | 317 |
| 2022 | 353 |
| 2023 | 371 |
| 2024 | 257 |
| 2025 | 202 |
| 2026 | 188 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,026 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pyrexiaSignal | 517 | 7.6 | 7.0 | 3,009 |
| influenzaSignal | 131 | 6.0 | 5.1 | 541 |
| pneumoniaSignal | 246 | 3.9 | 3.4 | 528 |
| urticariaSignal | 118 | 3.6 | 3.0 | 219 |
| coughSignal | 187 | 3.4 | 3.0 | 318 |
| inappropriate schedule of product administrationSignal | 119 | 3.4 | 2.8 | 197 |
| nasopharyngitisSignal | 107 | 3.0 | 2.5 | 138 |
| vomitingSignal | 207 | 2.2 | 2.0 | 144 |
| malaiseSignal | 190 | 2.2 | 1.9 | 127 |
| condition aggravatedSignal | 127 | 2.1 | 1.8 | 76 |
| dyspnoea | 198 | 1.8 | 1.6 | 69 |
| headache | 133 | 1.1 | 0.9 | 1 |
| pain | 128 | 1.1 | 0.9 | 0 |
| fatigue | 151 | 1.0 | 0.8 | 0 |
| death | 141 | 0.8 | 0.7 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.